Roche: to present oncology portfolio at 2017 ESMO Congress.
(CercleFinance.com) - Roche plans to present results from studies for 18 approved and investigational medicines to be presented at the European Society for Medical Oncology (ESMO) Congress from 8-12 September in Madrid.
They include phase III results from Roche's portfolio, e.g. Zelboraf and Alecensa, updates on developments and an insight into the biology of cancer.
“Progress against cancer is accelerating... leading to increasingly tailored treatment approaches,” said Sandra Horning, Roche's Chief Medical Officer and Head of Global Product Development. She concluded, saying “we look ahead to an unprecedented number of key milestones over the next 12 months.”
Copyright (c) 2017 CercleFinance.com. All rights reserved.
They include phase III results from Roche's portfolio, e.g. Zelboraf and Alecensa, updates on developments and an insight into the biology of cancer.
“Progress against cancer is accelerating... leading to increasingly tailored treatment approaches,” said Sandra Horning, Roche's Chief Medical Officer and Head of Global Product Development. She concluded, saying “we look ahead to an unprecedented number of key milestones over the next 12 months.”
Copyright (c) 2017 CercleFinance.com. All rights reserved.